Lupisit D 10mg/50mg Tablet

The synergistic action of these agents improves glycemic control without significant risk of hypoglycemia when used appropriately. Lupisit D is recommended as adjunctive therapy to diet and exercise in patients inadequately controlled on monotherapy or as initial combination therapy in specific cases. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or severe renal impairment.

Common adverse effects include urinary tract infections, nasopharyngitis, and gastrointestinal disturbances. Caution is advised in patients with a history of hypersensitivity, renal dysfunction, or volume depletion. Regular monitoring of renal function, glycemic parameters, and hydration status is essential during treatment. Lupisit D offers an effective option for optimizing glycemic control in type 2 diabetes, contributing to improved metabolic outcomes and reduced risk of diabetes-related complications.